bpc 157 human clinical data safety The Hidden Risks of BPC‑157: What Patients Need to Know About Contamination and bpc-157 human clinical trials evidence

All patients recruited were: (i) between 20 and 80 years of age

1 A dedicated human safety and tolerability evaluation supported an acceptable short-term profile at the doses tested, 8 and later characterization framed the ingredient as having a favorable safety and metabolism profile in the sponsors view

In individuals with symptomatic B 12 deficiency despite normal dietary B 12 intake, B 12 malabsorption is the most likely cause and should guide parenteral therapy

100% ABSORPTION

Store lyophilized at -20C

For example, some physicians prefer Voluma because it swells as it attracts and holds onto more water with time, and that gives it more of a lift over time